Ardelyx Q2 net loss narrows to $26.9M; IBSRELA sales start at $1.6M

ARDELYX, INC.

2022-Q2 EPS reported -$0.40 revenue$2,994,000

Net product sales of IBSRELA were $1.6M in Q2 2022, first commercial quarter post-launch.
Net loss $26.9M ($0.19/share) vs $45.2M ($0.45) in Q2 2021; cash & investments $81.0M.
Entered $20M financing with HealthCare Royalty based on future royalties from Kyowa Kirin.
FDA advisory committee for XPHOZAH NDA tentatively scheduled for Nov 16, 2022.
Survey data: 41% of GIs report using IBSRELA; 92% rate it as a substantial/moderate advance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.